Fig. 1From: Continued efforts to translate diabetes cardiovascular outcome trials into clinical practiceA treatment algorithm based on cardiac and renal co-morbidities and CVOTs. 1To be used with caution because of the risk of hypoglycemia; 2consider dose reduction (except for linagliptin) and monitor eGFR frequently; 3preferred in the presence of marked insulin resistance; 4initiation of therapy currently not recommended. aUKPDS; bPROACTIVE trial; cSAVOR; dTECOS, eEXAMINE; fLEADER trial; gEMPA-REG Outcome trial; hORIGIN trial; kADVANCE; jELIXA; mDIGAMI 1Back to article page